For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| License and development support revenue (including related party amounts of 0 and 251, respectively) | 0 | 251 | ||
| Research and development (including related party amounts of 76 and 3,168, respectively) | 69,540 | 50,328 | ||
| General and administrative | 20,270 | 17,205 | ||
| Total operating expenses | 89,810 | 67,533 | ||
| Loss from operations | -89,810 | -67,282 | ||
| Interest income | 5,959 | 5,349 | ||
| Change in fair value of safes (including related party amounts of 0 and 2,911, respectively) | 0 | -3,597 | ||
| Other (expense) income, net | -14 | 157 | ||
| Total other income, net | 5,945 | 1,909 | ||
| Loss before provision for income taxes | - | -65,373 | ||
| Provision for income taxes | - | 0 | ||
| Net income (loss) | -83,865 | -65,373 | ||
| Unrealized gain (loss) on investments | - | -437 | ||
| Unrealized gain (loss) on investments, net | 232 | - | ||
| Comprehensive loss | -83,633 | -65,810 | ||
| Basic EPS | -3.43 | -5.81 | ||
| Diluted EPS | -3.43 | -5.81 | ||
| Basic Average Shares | 24,444,057 | 11,258,851 | ||
| Diluted Average Shares | 24,444,057 | 11,258,851 | ||
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)